Teva completes Phase 3 asthma inhaler trial; registers vitiligo program and five ANDA actionsNov 6Weekly roundup, 8 itemsalbuterolduvakitug
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
FDA approves Teva's Weltruza, an extended release injectable olanzapineOct 8Regulatory decisionolanzapine
Teva posts Q2 2026 GAAP loss on Emalex charge, raises innovative brand outlookJul 29Quarterly updatedeutetrabenazinefremanezumab-vfrm